ClinicalTrials.gg
Active, not recruitingNCT05966194KEVLARxUpdated Jun 26, 2026

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

A Phase 2 interventional study of RRx-001 and Intensity Modulated Radiation Therapy (IMRT) in Oral Mucositis, sponsored by EpicentRx, Inc.. Active, not recruiting at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by EpicentRx, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Stomatitis with a site in United States — 12 open to participants now, 15 under way, none of them phase 3. Stomatitis · United States.

Planned enrollment
8th of 73
216 · median 60
Started
2024
with 2 others
Phase 2
33 of 80
2 open now
Primary completion
2027-07
later than 6 of 14 live
Registered
69th of 80
by date
Lead sponsor
2 of 80
EpicentRx, Inc.

Among the 80 studies in Stomatitis with a site in United States, this one is the 8th largest by planned enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2024, is one of 33 in phase 2, reaches primary completion later than 6 of the 14 other live ones, and was the 69th registered.

Stomatitis

307 studies on the registry are indexed under Stomatitis; 74 are open to participants now.

Browse Stomatitis studies →

Open to participants now

12 of the 80 studies in Stomatitis with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Stomatitis studies recruiting now, 20 (44%) set no upper age limit and 21 (47%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Stomatitis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients will receive RRx-001 or placebo before start of standard of care treatment.

Read the detailed description

The standard treatment for head and neck cancer currently includes a chemotherapy drug called cisplatin that is given by intravenous (IV) infusion and radiation, which is delivered from a machine that precisely targets the tumor. One common and unfortunate side effect of treatment with cisplatin and radiation is oral mucositis, which refers to irritation of the lining of the mouth. Oral mucositis is a serious problem 1) because the open mouth sores from oral mucositis may lead to severe pain, nutritional problems and dehydration from an inability to eat and drink, an increased risk of infection from bacteria and fungus and delay or discontinuation of treatment and 2) because there is only one approved therapy to treat or prevent it.

03

Conditions studied

  • Oral Mucositis

Keywords

  • Head and Neck Cancer
  • Neck cancer
  • Oral cancer
  • Mucositis
  • Squamous cell carcinoma (SCC)
  • HPV
  • Oropharynx
  • Oral cavity
  • IMRT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of squamous cell carcinoma (SCC) of the oral cavity or oropharynx Note: Patients with primary cancers that are presumed to be of oropharyngeal origin may be included if they meet radiation field dosing criteria as specified in Inclusion Criterion #2 below. Unknown primaries which are HPV+ are acceptable. HPV determination must be made for all patients.
  2. Radiation Treatment planned to receive standard IMRT with daily fractions of 2.0 to 2.2 Gy for a total cumulative dose of 60-72 Gy in conjunction with definitive or chemotherapy. Planned radiation treatment fields must include at least two oral sites (soft palate, floor of mouth, buccal mucosa, tongue) that are each planned to receive a total of > 55 Gy. Patients who have had prior surgery are eligible, provided they have fully recovered from surgery, and patients who may have surgery in the future are eligible.
  3. performance status ≤ 2.
  4. Participants must have adequate organ and marrow function as defined below:

    • (ANC) ≥ 1,500 / mm3 2. ≥ 75,000 / mm3 3. ≥ 9.0 g/dL
  5. Adequate renal and liver function as indicated by:

    • Serum creatinine acceptable for treatment with cisplatin per institutional guidelines) 2. Total ≤ 1.5 x upper-normal limit () 3. (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN 4. Alkaline phosphatase ≤ 2.5 x ULN
  6. Human papilloma virus (HPV) status in tumor must be documented using tumor immunohistochemistry for HPV-p16 or other accepted test (such as such as in situ hybridization) for patients with cancers of the oropharynx (Rooper et al, 2016, Martens 2017). HPV status at baseline optional for oral cavity tumors.
  7. Age 18 years or older
  8. Patient must consent to the access, review, and analysis of previous medical and cancer history, including imaging data, by the sponsor or a third party nominated by the sponsor.
  9. Ability and willingness to understand and sign a written document.
  10. Women of and men with partners of child-bearing potential must agree to use adequate (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.

    Note: A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been for at least 12 consecutive months
  11. Adequate visual access to permit examination of the following oral cavity sites: lips, buccal mucosa, floor of mouth, ventral and lateral tongue, and soft palate.

Exclusion criteria

Exclusion Criteria:

  1. Prior radiotherapy to the head and neck region.
  2. Prior induction chemotherapy.
  3. Tumors of the lips, salivary gland, nasopharynx, hypopharynx, or larynx.
  4. Patients with simultaneous primaries
  5. Stage IV, M1 (distant )
  6. Prior or current use of approved or anticancer agent other than those provided in this study.
  7. Grade 3 or 4 dysphagia or odynophagia (National Cancer Institute Common Toxicity Criteria, version 5.0) or inability to eat a normal (solid) diet
  8. Requirement at baseline for parenteral or gastrointestinal tube-delivered nutrition for any reason or prophylactic insertion of gastrostomy tube with dependency on tube feeding at baseline.
  9. Malignant tumors other than squamous cell carcinoma of the head and neck within last 5 years, unless treated definitively and with low risk of recurrence in the judgment of the treating investigator.
  10. Active infectious disease excluding oral candidiasis.
  11. Presence of oral mucositis (WHO Score ≥ Grade 1) or other oral mucosal ulceration at baseline.
  12. Untreated active oral or dental infection
  13. Known history of or active or C.
  14. Any significant medical diseases or conditions, as assessed by the investigators and sponsor that would substantially increase the medical risks of participating in this study (e.g, , uncontrolled diabetes, II-IV congestive heart failure, myocardial infarction within 6 months of study, severe chronic pulmonary disease or active uncontrolled infection, uncontrolled or pulmonary edema)
  15. Use of the following within 48 hours of enrollment and duration of Oral Mucositis follow up: vitamin B12 (cobalamin) or synthetic vitamin B12, cyanocobalamin, or the vitamin B12 precursor, cobinamide, or any supplement or multivitamin with vitamin B12 or vitamin E in it since both vitamin B12 and vitamin E interact negatively with RRx-001.
  16. Use of prebiotics and probiotics
  17. Pregnant or nursing.
  18. Known allergies or intolerance to cisplatin or other platinum-containing compounds.
  19. Sjogren syndrome
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    RRx-001 Pre-Treatment (8mg RRx-001) + Chemoradiation Therapy (CRT)

    Pretreatment consists of 8 mg RRx-001 given twice weekly during the 2 weeks prior to the start of CRT (4 doses total) followed by the CRT treatment period

    Drug: RRx-001 · Radiation: Intensity Modulated Radiation Therapy (IMRT) · Drug: Cisplatin for injection 100 mg/m2

  • Experimental
    RRx-001 Pre-Treatment (4mg RRx-001) + Chemoradiation Therapy (CRT)

    Pretreatment consists of 4 mg RRx-001 given twice weekly during the 2 weeks prior to the start of CRT (4 doses total) followed by the CRT treatment period.

    Drug: RRx-001 · Radiation: Intensity Modulated Radiation Therapy (IMRT) · Drug: Cisplatin for injection 100 mg/m2

  • Placebo comparator
    Placebo Pre-Treatment + Chemoradiation Therapy (CRT)

    No doses of RRx-001 will be administered. Patients assigned to this arm will receive placebo twice weekly during the 2 weeks prior to the start of CRT followed by the CRT treatment period.

    Radiation: Intensity Modulated Radiation Therapy (IMRT) · Drug: Cisplatin for injection 100 mg/m2

Interventions

  • RRx-001 for injection (4 mg or 8 mg)

  • RadiationIntensity Modulated Radiation Therapy (IMRT)

    Intensity Modulated Radiation Therapy of up to 72 Gy

  • DrugCisplatin for injection 100 mg/m2

    Drug page: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cisplatin for injection 100 mg/m2

06

What researchers measure

Primary outcomes

  1. Incidence of Severe Oral Mucositis (SOM) through Intensity-modulated radiation therapy (IMRT)

    The incidence of SOM defined as the proportion of patients with any WHO Grade \>= 3 (severe to life threatening) oral mucositis during the observation period from the start of CRT through IMRT

    Time frame: Estimated up to 18 Months

Secondary outcomes

  1. Duration of Severe Oral Mucositis (SOM) through Intensity-modulated radiation therapy (IMRT)

    Duration of SOM (through the last day of radiation therapy, DoSOM). Its principal analysis employs the probability of being in response (PBIR), an intuitive concept based on the realization that the duration of response which is quantified as the area under the curve delimited by the duration of exposure (x axis) and the response probability (y axis).

    Time frame: Estimated up to 18 Months

  2. Duration of Severe Oral Mucositis (SOM) through 60 Gy

    Duration of SOM (through 60 Gy, DoSOM) is compared between RRx-001 arms and Placebo using a two-sided log-rank test.

    Time frame: Estimated up to 18 Months

  3. Time to onset of Sever Oral Mucositis (ttSOM)

    Time onset to SOM (ttSOM) is defined as the time interval measured from the start of the observation period to the first time SOM is observed.

    Time frame: Estimated up to 18 Months

  4. Incidence and severity of dysphagia

    Incidence and severity of dysphagia will be analyzed similarly to the primary efficacy endpoint.

    Time frame: Estimated up to 18 Months

  5. Cumulative radiation dose to onset of SOM

    Cumulative radiation dose to onset of SOM is compared between RRx-001 arms and placebo

    Time frame: Estimated up to 18 Months

  6. Incidence of grade 4 oral mucositis

    Incidence of grade 4 oral mucositis through 60 Gy

    Time frame: Estimated up to 18 Months

  7. Narcotic use through resolution of SOM

    Narcotic use through resolution of SOM will be analyzed similarly to the cumulative radiation dose

    Time frame: Estimated up to 18 Months

  8. Incidence of Severe Oral Mucositis through 60 Gy of the Radiation Treatment Plan

    incidence of SOM defined as the proportion of patients with any WHO Grade \>= 3 (severe to life threatening) oral mucositis during the observation period from the start of CRT through 60 Gy

    Time frame: Estimated up to 18 Months

  9. Progression free survival (PFS)

    Progression free survival (PFS)

    Time frame: Estimated up to 24 Months

  10. Degree of Xerostomia

    Degree of Xerostomia as analyzed by validated Xerostomia questionnaire 'XQ'

    Time frame: Estimated up to 24 Months

  11. Xerostomia duration

    Xerostomia duration as analyzed by validated Xerostomia questionnaire 'XQ'

    Time frame: Estimated up to 24 Months

  12. Time to onset of dysphagia

    Time to onset of dysphagia

    Time frame: Estimated up to 24 Months

  13. Duration of dysphagia

    Duration of dysphagia

    Time frame: Estimated up to 24 Months

07

Study locations

14 sites
08

References and documents

Publications

  • Bonomi M, Blakaj DM, Kabarriti R, Colvett K, Takiar V, Biagioli M, Bar-Ad V, Goyal S, Muzyka B, Niermann K, Abrouk N, Oronsky B, Reid T, Caroen S, Sonis S, Sher DJ. PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):551-559. doi: 10.1016/j.ijrobp.2022.12.031. Epub 2023 Jan 14. PubMed 36646388 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jul 2027, 38 months after the start.

Of 39 phase 2 interventional studies under Stomatitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Jul 28, 2023
StartActual
Apr 2, 2024
Primary completionEst.
Jul 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05966194
Lead sponsor
EpicentRx, Inc.
Responsible party
Sponsor
First posted
Jul 28, 2023
Start date
Apr 2, 2024
Primary completion
Jul 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Jun 26, 2026

Study contacts

Meaghan Stirn
study director · EpicentRx, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RRx-001

Start the discussion